Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Moscow Clinical Scientific Center (Moscow, Russian Federation)
    2. Medical Radiological Research Center name by A. F. Tsyb (Moscow, Russian Federation)

    Keywords:mesenchymal stromal cells,reparative processes,inflammatory bowel diseases,model of colitis

    Abstract:Transplantation of allogenic mesenchymal stromal cells (MSCs) is used for the stimulation of reparative processes in various organs and tissues. The aim of our work was to assess the reparative potential of MSCs to bone marrow in acute and chronic damage to the intestines of Wistar rats induced by sodium dextran-sulfate (DS). An experiment to study the reparative capacity and safety of transplantation of MSCs bone marrow in acute and chronic intestinal damage induced by sodium DS was carried out on Wistar rats. Transplantation of mesenchymal stromal cells in this experiment showed improvement of the histological picture of the intestinal mucosa. Experience has demonstrated the feasibility of this method in the field of medical use of stem cells the type that is aimed at increasing the effectiveness of therapy of chronic inflammatory bowel diseases.

      1. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6: 523-644.
      2. Timothy J., Nelson, M.D., Ph.D., Atta Behfar, M.D., Ph.D., and Andre Terzic, M.D., Ph.D. Strategies for Therapeutic Repair: The “R 3” Regenerative Medicine Paradigm. Clin Transl Sci. 2008 September 10; 1(2): 168-171.
      3. Князев О. В., Парфенов А. И., Щербаков П. Л., Хомерики С. Г., Ручкина И. Н., Конопляников А. Г. Эффективность и безопасность мезенхимальных стромальных клеток костного мозга у больных с рефрактерными формами болезни Крона. Клеточная трансплантология и тканевая инженерия. Том VIII, № 1, 2013, стр. 76-84.
      4. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut. 2011;60:788-798.
      5. Doorn J, Moll G, Le Blanc K, et al. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev. 201218:101-115.
      6. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study.Gut. 2010;59:1662-1669.
      7. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol Mech Dis. 2011;6:457-478.
      8. DelaRosa O, Lombardo E, Beraza A, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A. 2009;15:2795-2806.
      9. Maccario R, Podest`a M, Moretta A, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD 4 + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005;90:516-525.
      10. Meisel R, Zibert A, Laryea M, et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004;103:4619-4621.
      11. Griffin MD, Ryan AE, Alagesan S, et al. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol. 2013; 91:40-51.
      12. Ceron W, Lozada-Requena I, Ventocilla K, Jara S, Pinto M, Cabello M, Aguilar JL. Mesenchymal stem cells: definitions, culture and potential applications. Rev Peru Med Exp Salud Publica. 2016 Oct-Dec;33(4):758-771. doi: 10.17843/rpmesp.2016.334.2563.

    Full text is published :
    Knyazev O.V., Khomeriki S.G., Trubitsyna I.E., Konoplyannikov A.G. TRANSPLANTATION OF MESENCHYMAL STROMAL CELLS OF BONE MARROW ON THE MODEL OF ULCERATIVE COLITIS. Experimental and Clinical Gastroenterology Journal. 2017;144(08):62-66
    Read & Download full text

    1. Pirogov Russian National Research Medical University (Moscow, Russian Federation)
    2. Krasnoyarsk State Medical University named after Prof. V. F. Voino-Yasenetsky (Moscow, Russian Federation)
    3. Federal State Autonomous Institution “National Scientific and Practical Center of Children’s Health” Of the Ministry of Health of the Russian Federation (Moscow, Russian Federation)

    Abstract:Objective: to develop an algorithm for step-by-step differential diagnosis of congenital cholestatic diseases in children based on a multifactorial statistical analysis of the characteristics of the course of diseases for their early detection and determination of the tactics of medical care. Patients and research methods. 81 children aged 1 month to 16 years (average age 5 years 2 months ± ± 6 months), of which 20 children with biliary atresia (BA), 17 children with hereditary tyrosinemia type 1 (HT1), 23 children with progressive familial intrahepatic cholestasis (PFIHC), 21 children with Alagilla syndrome (SA). Were performed retrospective analysis of the history and clinical manifestations of disease in the debute; biochemical blood examination; hepatobiliscintiraphy (HBSH). Results. It was found that the most significant clinical symptoms at the onset of congenital cholestatic disease in infants is prolonged jaundice in the neonatal period, hypocolia or Acholia of the stool, hepatomegaly or hepatosplenomegaly in children born with intrauterine hypotrophy from pregnancy, which was threatened with interruption. Dyspepsia syndrome, fever, and rickets in disease onset is characteristic of hereditary tyrosinemia type 1. It has been proven that using HBSH differentiates the type of intrahepatic cholestasis - intracellular sinusoidal from ductular, as well as differentiation of PFIHC and BA from SA and NT1, for example, metabolic diseases involving liver pathology are considered. It is shown that the most significant laboratory parameters in the differential diagnosis of cholestatic diseases in young children are the levels of gammaglutamyltranspeptidase (GGT), total bilirubin with a predominance of direct fraction and alanine aminotransferase (ALT). A set of indicators of changes in GGT, ALT, and bilirubin allows to differentiate congenital cholestatic disease. An algorithm for step-by-step differential diagnosis of congenital cholestatic diseases in young children has been developed. Conclusions. A timely, step-by-step differential diagnosis of congenital cholestatic diseases in children allow early detection of these diseases and determine the correct patient management tactics, including screening for the necessary surgical treatment. Early differential diagnosis of cholestasis in infants will allow to prevent disability in children, as well as to influence such a significant indicator as infant and child mortality.

      1. Russo P, Magee JC, Boitnott J, Bove KE, Raghunathan T, Finegold M, Haas J, Jaffe R, Kim GE, Magid M, Melin-Aldana H, White F, Whitington PF, Sokol RJ. Design and validation of the biliary atresia research consortium histologic assessment system for cholestasis in infancy. Clin Gastroenterol Hepatol. - 2011;9:357-62e2.
      2. Azar G, Beneck D, Lane B. Atypical morphologic presentation of biliary atresia and value of serial liver biopsies. J Pediatr Gastroenterol Nutr. - 2002;34:212-5.
      3. Hwa Pyung Lee, Ben Kang, So Yoon Choi, Sanghoon Lee, Suk-Koo Lee, Yon Ho Choe. Outcome of Alagille Syndrome Patients Who Had Previously Received Kasai Operation during Infancy: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. - 2015 Sep. 18(3): 175-179.
      4. Hartley J, Harnden A, Kelly D. Biliary atresia. BMJ 2010;340: c2383.
      5. El-Guindi MA, Sira MM, Sira AM, Salem TA, El-Abd OL, Konsowa HA, El-Azab DS, Allam AA. Design and validation of a diagnostic score for biliary atresia. Journal of hepatology 2014; 61(1): 116-23.
      6. Gupta DK, Srinivas M, Bajpai M. AIIMS clinical score: a reliable aid to distinguish neonatal hepatitis from extra hepatic biliary atresia. Indian journal of pediatrics 2001; 68(7): 605-8.
      7. El-Guindi MA, El-Said HH, Hussein MH, Nassar RE, Sira AM. Urinary urobilinogen in biliary atresia: A missed, simple and cheap diagnostic test. Hepatology research: the official journal of the Japan Society of Hepatology 2015.
      8. Tiao MM, Tsai SS, Kuo HW, Chen CL, Yang CY. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. Journal of gastroenterology and hepatology 2008; 23(1): 62-6.
      9. Mieli-Vergani G, Vergani D. Biliary atresia. Semin Immunopathol 2009; 31(3): 371-81.
      10. Yang JG, Ma DQ, Peng Y, Song L, Li CL. Comparison of different diagnostic methods for differentiating biliary atresia from idiopathic neonatal hepatitis. Clin Imaging 2009;33:439-46.
      11. Anshu Srivastava. Progressive Familial Intrahepatic Cholestasis. J Clin Exp Hepatol. 2014;4(1):25-36.
      12. Frongillo F, Bianco G, Silvestrini N. Acute Liver Failure in an Adult, a Rare Complication of Alagille Syndrome: Case Report and Brief Review. Transplant Proc. 2015 Sep;47(7):2179-81.
      13. Дж. Г. Солвей. Наглядная медицинская биохимия / ГЭОТАР-Медиа. - 2011. - 136с
      14. Kaye AJ, Rand EB, Munoz PS, Spinner NB, Flake AW, Kamath BM. Effect of Kasai procedure on hepatic outcome in Alagille syndrome. J Pediatr Gastroenterol Nutr. 2010;51:319-321
      15. Holme E., Lindstedt S. Diagnosis and management of tyrosinemia type I. Curr Opin Pediatr. 1995; 7:726-32
      16. Полякова С. И., Савостьянов К. В., Пушков А. А. Наследственная тирозинемия 1-го типа - что нужно знать педиатрам. Практика педиатра. 2014 февраль, с. 4-16
      17. Sokol RJ, Mack C, Narkewicz MR, Karrer FM. Pathogenesis and outcome of biliary atresia: current concepts. J Pediatr Gastroenterol Nutr. 2003;37:4-21
      18. Davenport M, Grieve A. Maximizing Kasai portoenterostomy in the treatment of biliary atresia: medical and surgical options. S Afr Med J. 2012;102:865-867
      19. Cheremisinova I. S., Shakhov B. Е. Actual Radiodiagnosis Technologies of Hepatic Cancer. Sovremennye tehnologii v medicine. 2012; (4): 115-120
      20. Логинов А. С., Решетняк В. И. Механизм развития внутрипеченочного холестаза и лечение больных первичным билиарным циррозом печени: научное издание; 4 Рос. нац. конгр. «Человек и лекарство», Москва, 8-12 апр., 1997. - М., 1997. - С. 75.
      21. Sun S, Chen G, Zheng S, Xiao X, Xu M, Yu H, Dong R. Analysis of clinical parameters that contribute to the misdiagnosis of biliary atresia. J Pediatr Surg. 2013;48:1490-1494
      22. Tang KS, Huang LT, Huang YH, Lai CY, Wu CH, Wang SM, Hwang KP, Huang FC, Tiao MM. Gamma-glutamyl transferase in the diagnosis of biliary atresia. Acta Paediatr Taiwan. 2007;48:196-20
      23. Liu C, Aronow BJ, Jegga AG, Wang N, Miethke A, Mourya R, Bezerra JA. Novel resequencing chip customized to diagnose mutations in patients with inherited syndromes of intrahepatic cholestasis. Gastroenterology. 2007;132(1):119-26.
      24. Pawlikowska L., Strautnieks S., Jankowska I. Differences in presentation and progression between severe FIC 1 and BSEP deficiencies. J Hepatol. 2010;53:170-178
      25. Martinez AM, Cedilos CAM, Zermeno JN. Dermatologic manifestations of Alagille syndrome. Bol Med Hosp Infant Mex. 2012;69(2):132-36.

    Full text is published :
    Volynets G.V., Khavkin A.I., Panfilova V.N., Nikitin A.V. DIFF ERENTIAL DIAGNOSIS OF CONGENITAL CHOLESTATIC DISEASES IN CHILDREN. Experimental and Clinical Gastroenterology Journal. 2017;144(08):67-74
    Read & Download full text